Company intelligence / Profile preview

Allyx Therapeutics

New Haven, Connecticut, United Statesallyxthera.com ↗

Ownership: Private
Development stage: Phase 1

Overview

ALX-001, the company's lead compound, has completed Phase 1a trials showing it is safe and well-tolerated at all doses and achieves full brain receptor occupancy. The company is currently conducting Phase 1b studies in Alzheimer's disease and has begun treating patients with Parkinson's disease in a separate clinical study. A Phase II proof of concept study is being planned.

Therapeutic areas: Neurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

BMS-9894923

Partnerships

Bristol Myers Squibb (licensing agreement)Yale School of Medicine (licensing agreement)

Beyond the preview

Go deeper on Allyx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allyx Therapeutics.

Explore the full profile